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IL-10 Underlies Distinct Susceptibility of BALB/c and C57BL/6
Mice to Mycobacterium avium Infection and Influences Efficacy
of Antibiotic Therapy1
Susana Roque,*† Claudia Nobrega,†‡ Rui Appelberg,†‡ and Margarida Correia-Neves2*†
Increased production of IL-10 has been frequently associated with augmented susceptibility to infection. However, the correlation
between IL-10 activity and susceptibility to mycobacterial infection is still uncertain. Although studies using transgenic mice
overexpressing IL-10 consistently showed an increased susceptibility to mycobacterial infection, experimental approaches in which
IL-10 activity was reduced or abrogated originated inconclusive data. We show here that this controversy might be due to the
mouse strains used in the various experimental procedures. Our results show that BALB/c mice are more susceptible than
C57BL/6 to Mycobacterium avium infection. This increased susceptibility of BALB/c mice is, to a great extent, due to distinct
activity of IL-10 between the two mouse strains. In accordance, reduction of IL-10 activity through the administration of anti-
IL-10R mAb, or the absence of IL-10 as studied in IL-10 knockout mice, clearly decreased the susceptibility of BALB/c mice to
M. avium but had a less obvious effect in C57BL/6 mice. Moreover, abrogation of IL-10 activity in infected BALB/c mice increased
the efficacy of antimycobacterial therapy, whereas for the C57BL/6 mice it produced no effect. These observations show that the
activity of IL-10 in response to the same mycobacterial stimulus influences not only the susceptibility to infection but also the
efficacy of antimycobacterial therapy. This should now be considered in the context of human response to mycobacterial infection,
particularly as a possible strategy to improve treatment against infections by mycobacteria. The Journal of Immunology, 2007,
178: 8028–8035.
M ice have been extensively used to study the immuneresponse to infection and the availability of numerousinbred strains has allowed the establishment of models
of resistance or susceptibility to infection by many different mi-
crobial pathogens. A classical example is the use of different
mouse strains to analyze Leishmania major infection, which led to
the in vivo demonstration of the Th1/Th2 paradigm and the rela-
tionship between T cell subsets and resistance/susceptibility to this
pathogen. In the L. major model, C57BL/6 mice are more resistant
whereas BALB/c mice are fully susceptible (1). A similar dichot-
omy between the resistance/susceptibility of these two mouse
strains has also been found in experimental infections by Listeria
monocytogenes (2) and by Yersinia enterocolitica (3).
One of the cytokines strongly associated with the increased sus-
ceptibility to infection in mice is IL-10 (4–7). This cytokine is
essential for dampening the inflammatory response once the infec-
tion has been controlled (8) and is produced by different popula-
tions of T and B lymphocytes, macrophages, and dendritic cells.
The most obvious effect of IL-10 is to inhibit the production of
proinflammatory cytokines by different cells of the immunological
system (8). The role of IL-10 in determining the host’s suscepti-
bility to infection by intracellular pathogens has thus drawn much
attention in recent years (8, 9). Studies with L. monocytogenes,
using either transgenic mice overexpressing IL-10 or the admin-
istration of rIL-10 to wild-type mice, have shown that IL-10 ac-
tivity directly correlates with susceptibility to infection (10, 11). In
agreement, blocking IL-10 activity enabled infected mice to con-
trol infection with an otherwise lethal dose of L. monocytogenes
(6). Similarly, increased resistance to infection was also observed
for Leishmania spp. upon inhibition of IL-10 activity (4, 12, 13).
Overall, these studies were concordant and showed that IL-10 in-
creases susceptibility to infection by certain intracellular patho-
gens (9).
The role of IL-10 in determining susceptibility to mycobacterial
infections is still not clear. Whereas transgenic mice overexpress-
ing IL-10 were consistently more susceptible than wild-type mice
to infection by Mycobacterium bovis bacillus Calmette-Gue´rin,
Mycobacterium avium, or Mycobacterium tuberculosis (14–16),
depletion studies generated less consistent data. Thus, although the
use of IL-10- or IL-10R-blocking Abs led to a reduced multipli-
cation of M. avium (17–19), the analysis of IL-10 knockout (KO)3
mice showed that they could be either more resistant to infection
or as resistant as wild-type animals (20–24). Among the possible
reasons for the discrepancies observed is the genetic background
of the different mouse strains used in the various studies. Thus,
although studies assessing the role of IL-10 in susceptibility to
mycobacteria using blocking Abs used either the C57BL/6 or the
BALB/c strains, all studies on IL-10 KO animals were done using
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pure C57BL/6 or mix C57BL/6.129 backgrounds. In fact, myco-
bacterial infection has been shown to differentially influence IL-10
production in different mouse strains; BALB/c mice present higher
secretion than C57BL/6 (25). Results from Turner et al. (16) also
showed that CBA/J mice produce more IL-10 within macrophage-
rich tuberculosis lesions and exhibit higher mycobacterial loads in
the lung when compared with C57BL/6 mice.
The relevance of IL-10 in mycobacterial infections has gained
renewed interest given a set of observations in humans that repet-
itively associated the increased production of IL-10 with increased
susceptibility to infection. This has been the case for M. avium
infection for HIV-coinfected patients (26), for patients with tu-
berculosis (27–30), and for Mycobacterium ulcerans-infected
patients (31, 32).
In this study, we show that BALB/c mice are more susceptible
than C57BL/6 mice to M. avium infections and relate this differ-
ence in susceptibility with distinct IL-10 activity. Moreover, the
efficacy of antimycobacterial drugs was improved by abrogating
IL-10 activity in BALB/c but not in C57BL/6 mice. These findings
have implications for the design of adjunctive therapies in myco-
bacterial infections, namely the possibility of using IL-10-blocking
drugs in a subset of patients.
Materials and Methods
Animals
BALB/c and C57BL/6, 8- to 10-wk-old specific pathogen-free female mice
were purchased from Harlan Breeders and Charles River Laboratories.
IL-10 KO mice on a C57BL/6 background were purchased from The Jack-
son Laboratory. IL-10 KO mice on a BALB/c background were bred in our
facilities from two breeding pairs provided by Dr. A. O’Garra (National
Institute for Medical Research, London, U.K.). All mice were kept in ster-
ile housing conditions under 12-h light cycles and were given chow and tap
water or an antibiotic mixture ad libitum. All animal experiments were
performed in accordance with national and European guidelines for the
care and handling of laboratory animals and have been approved by the
National Veterinary Directorate.
Mouse infection and quantification of bacterial load in the
organs
Mice were infected i.v., through a lateral tail vein, with 106 CFU of M.
avium strain 2447 (smooth transparent variant, provided by Dr. F. Portaels,
Institute of Tropical Medicine, Antwerp, Belgium). At different time
points, mice were sacrificed and the organs (spleen, liver, and lung) were
collected, homogenized, serially diluted (0.04% Tween 80 in distilled wa-
ter), and plated onto Middlebrook 7H10 agar medium. The plates were
incubated for 1 wk at 37°C and the number of CFU were counted. When
antibiotics were given, their administration was stopped 48 h before sac-
rifice to avoid the effect of antibiotics on bacterial growth after plating.
In vivo blockage of IL-10 activity
Blockage of IL-10 activity was performed by the administration of an
anti-IL-10R mAb, an IgG1 obtained from the rat hybridoma cell line 1B1.2
(a gift from Dr. K. Moore, DNAX, Palo Alto, CA) (33). To block the
IL-10R, mice were injected i.p. with 0.5 mg of anti-IL-10R mAb 24 h
before or 4 wk after infection (depending on the specific experiment),
followed by i.p. injections with 0.2 mg of anti-IL-10R mAb every other day
during 4 wk or for the rest of the experimental infection (depending on the
specific experiment). Control mice were submitted to the same protocol of
administration of Abs, being injected with nonimmune rat IgG (obtained
from sera of Lewis rats). Both Abs were purified by affinity chromatogra-
phy using a protein-G agarose column (Sigma-Aldrich), followed by dial-
ysis against PBS.
Antibiotic regimens
The antimycobacterial therapy was initiated 4 wk after infection, with a
mixture of antibiotics consisting of rifampicin (Sigma-Aldrich), clarithro-
mycin (Abbott Laboratories), and ethambutol (Sigma-Aldrich). The mix-
ture of antibiotics was either administered ad libitum in the drinking water
or administered by gavage. The mixture administered in the drinking water
contained 0.4 mg/ml rifampicin, 1.94 mg/ml clarithromycin, and 0.25
mg/ml ethambutol on sterile tap water (19). Each mouse drank on average
3 ml/day. Chemotherapy against M. avium given by gavage consisted of
4.67 mg/ml rifampicin, 22.5 mg/ml clarithromycin, and 2.92 mg/ml etham-
butol on sterile tap water. Each mouse was administered 0.3 ml of antibi-
otics 6 days a week. It should be noted that, on average, all mice received
the same dose of antibiotic per week, whether the administration was done
by gavage or ad libitum.
Detection of IFN- and TNF in serum samples
To obtain serum, mice were anesthetized with isoflurane (Abbott Labora-
tories) and retro-orbital bleeding was performed before sacrifice. Blood
was allowed to clot and the serum was collected after centrifugation and
frozen at 80°C until use.
Quantification of IFN- in sera was done by a two-side sandwich ELISA
with anti-IFN--specific affinity-purified mAbs (R4-6A2 as capture and
biotinylated AN-18 as detecting mAbs) and the standard curves were gen-
erated with known amounts of IFN- (PeproTech). The sensitivity of the
assay was 20 pg/ml.
A Cytometric Bead Array (CBA) kit to detect inflammatory cytokines
(BD Biosciences) was used to measure TNF in serum samples using a
FACSCalibur flow cytometer (BD Biosciences). The sensitivity of the as-
say for TNF according to the CBA kit specifications was 20 pg/ml.
FIGURE 1. BALB/c are more susceptible to M. avium infection than
C57BL/6 mice. BALB/c and C57BL/6 mice were infected i.v. with 106
CFU of M. avium. Bacterial load was determined at different time points (1
day, 2, 4, and 9 wk) in spleen and liver. Each point represents the mean 
SD of the CFU from six mice per group from one of six independent
experiments.
FIGURE 2. Splenocytes from BALB/c mice secrete more IL-10 in vitro
than C57BL/6. Splenocytes from BALB/c and C57BL/6 mice noninfected
and infected with M. avium (for 2 and 4 wk) were stimulated with Con A
(5 g/ml) for 72 h. IL-10 concentration was determined by ELISA in
culture supernatants. Data are represented as the mean  SD of IL-10
concentration from five mice per group from one of two independent
experiments.
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In vitro stimulation of splenic cells and IL-10 measurement
Single-cell suspensions were obtained from the spleen of BALB/c and
C57BL/6 mice. Erythrocytes were lysed with a hemolytic solution (155
mM NH4Cl, 10 mM KHCO3 (pH 7.2)) during 5 min at room temperature.
Cells were then distributed into 96-well plates (2.5  105 cells/well), and
incubated in triplicate in DMEM (Invitrogen Life Technologies), supple-
mented with 10% heat-inactivated FBS (Invitrogen Life Technologies) 2
mM L-glutamine (Invitrogen Life Technologies), 1 mM sodium pyruvate
(Invitrogen Life Technologies), 10 mM HEPES (Invitrogen Life Technol-
ogies), 50 U/ml penicillin, 50 g/ml streptomycin (Invitrogen Life Tech-
nologies), and either with no further stimulus or with 5 g/ml Con A
(Sigma-Aldrich). Supernatants were collected after 3 days of culture and
the concentration of IL-10 measured by ELISA (Duo Set; R&D Systems).
The sensitivity of the assay was 32.5 pg/ml.
Flow cytometry
For each immunofluorescence staining for flow cytometry, 5  105 cells
were used from each individual mouse and incubated with a specific Ab for
20 min at 4°C. Cell surface markers were analyzed using anti-CD25 allo-
phycocyanin, anti-CD25 PE, anti-CD11b PE, anti-CD3 FITC, anti-CD4
FITC (BD Pharmingen), and anti-CD4 PECy5 (BioLegend). All cells were
fixed with 2% formaldehyde after staining. The analysis of the cell popu-
lations was based on the acquisition of 30,000 events using CellQuest
software on a FACSCalibur flow cytometer or a FACSAria cell sorter (BD
Biosciences).
For the analysis of Foxp3 intracellular expression, cells were first
stained for the surface molecules and, after fixation and permeabilization,
were incubated with anti-Foxp3 FITC (eBioscience) based on the manu-
facturer’s recommendations.
For intracellular detection of IL-10, 5  105 cells were stimulated with
PMA (50 ng/ml; Sigma-Aldrich) and ionomycin (500 ng/ml; Sigma-
Aldrich) for 4 h. Brefeldin A (10 g/ml; Sigma-Aldrich) was added to the
culture during the last 2 h of stimulation. Cells were harvested, washed, and
stained for the expression of surface molecules. Cells were fixed with 2%
formaldehyde and permeabilized with 0.5% saponin. After permeabiliza-
tion, the FcRs were blocked with Fc-Block (BD Pharmingen) and the cells
were stained with anti-IL-10 PE (BD Pharmingen) during 30 min, at room
temperature. The analyses of the intracellular stainings were based on the
acquisition of 50,000 events. Cells were analyzed using CellQuest software
on a FACSCalibur flow cytometer (BD Biosciences).
Infection and treatment of bone marrow-derived macrophages
(BMDM)
BMDM were prepared from BALB/c, C57BL/6, and IL-10 KO mice on
BALB/c background, cultured in 24-well plates, as previously described
(34). On day 10 of culture, when the cells had completely differentiated
into macrophages, they were infected by adding 106 CFU of M. avium 2447
to each well containing 5  105 cells. Macrophages were then incubated
for 4 h at 37°C in a 7% CO2 atmosphere, washed with warm HBSS to
remove noninternalized bacteria, and reincubated in DMEM containing
10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, and
10% L929 cell-conditioned medium. In some wells, macrophages were
immediately lysed and the number of viable intracellular bacteria was de-
termined by counting the CFU after plating serial dilutions on Middlebrook
7H10 agar plates. In some experiments, macrophages were treated, just
after infection until day 5 postinfection, with daily doses of IFN- (1, 10,
and 100 U/well). In some experiments, supernatants were collected every
day and the IL-10 concentration was determined by ELISA (Duo Set; R&D
Systems). The sensitivity of the assay was 32.5 pg/ml. For each condition
tested, three culture wells were used.
Statistical analysis
Statistically significant differences between groups were determined using
the Student t test. Significance was referred like  for p  0.05 and like 
for p  0.001.
Results
BALB/c are more susceptible to M. avium infection than
C57BL/6 mice
BALB/c and C57BL/6 mice were infected i.v. with a strain of M.
avium of intermediate virulence (strain 2447 SmT) and the myco-
bacterial growth was followed for up to 9 wk. As shown in Fig. 1,
FIGURE 3. M. avium-infected C57BL/6
mice show higher IFN- and TNF serum
levels than BALB/c mice. IFN- concentra-
tion was determined in the serum by ELISA
(A) and TNF by CBA (B) before and 4 wk
after M. avium infection of BALB/c and
C57BL/6 mice. Data are represented as the
mean SD of IFN- or TNF concentrations
from five mice per group from one of two
independent experiments. BDL, Below de-
tection level.
FIGURE 4. Differences in the cell popu-
lation in the spleen of BALB/c and C57BL/6
M. avium-infected mice. Splenocytes from
M. avium-infected (2 and 4 wk postinfec-
tion) and noninfected BALB/c and C57BL/6
mice were stained with Abs specific for CD4
and CD25, CD4, CD25 and Foxp3, and
CD11b and analyzed by flow cytometry.
Data are represented as the mean  SD,
from five mice per group from one of two
independent experiments.
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spleen and liver from BALB/c mice presented higher bacterial
loads when compared with C57BL/6 mice. In a total of six exper-
iments performed, this difference was consistently observed from
4 wk after infection onward. Of notice, in two of these six exper-
iments, the increased bacterial load in BALB/c mice was already
present 2 wk after infection (data not shown). No consistent dif-
ferences in bacterial load were observed in the lungs of the two
mouse strains (data not shown).
BALB/c mice exhibit an increased ability to produce IL-10 in
vitro and decreased serum levels of IFN- and TNF when
compared with C57BL/6 mice during M. avium infection
Given the association between IL-10 production and genetically
determined susceptibility to some pathogens, we next studied the
production of IL-10 in the two mouse strains after infection with
M. avium. The amounts of IL-10 produced in vitro by splenocytes
from infected and noninfected mice upon stimulation with Con A
are shown in Fig. 2. When compared with C57BL/6, BALB/c
splenocytes displayed greater ability to secrete IL-10, both before
and upon M. avium infection, confirming previous results (25).
Similar results were observed when the cells were stimulated with
PMA and ionomycin (data not shown). Using two distinct tech-
niques, ELISA and CBA, we were unable to quantify IL-10 in the
sera from infected and noninfected mice. Because the production
of IFN- and TNF, key proinflammatory cytokines in the protec-
tive immune response against infection by mycobacteria, are
down-modulated by IL-10, we measured IFN- and TNF in the
sera of infected mice. As shown in Fig. 3, C57BL/6 mice presented
higher serum levels of IFN- and TNF than BALB/c mice at 4 wk
of infection.
BALB/c mice have higher numbers of IL-10-producing
CD4CD25 splenocytes than C57BL/6 mice
We next investigated which cell populations were responsible for
the increased IL-10 production by BALB/c splenocytes. To do so,
we first analyzed different cell populations in the spleen from non-
infected and infected mice of both strains. We observed no differ-
ences in the total number of CD4 (CD4CD3) and CD8
(CD8CD3) T cells or of B lymphocytes (CD19) (data not
shown). However, as shown in Fig. 4, the total number of
CD4CD25 as well as of CD4CD25Foxp3 cells in the
spleen was higher in BALB/c than in C57BL/6 mice before and 2
wk after infection (Fig. 4). Moreover, the total number of macro-
phages (CD11b) was also superior in the spleen of BALB/c 2 wk
postinfection (Fig. 4).
To understand whether these or other cells were responsible for
the increased production of IL-10 from BALB/c splenocytes, we
performed intracellular staining for IL-10 upon in vitro restimula-
tion of splenocytes from infected and noninfected mice of both
strains and analyzed the cells by flow cytometry. We found no
strain differences on the percentage of macrophages (CD11b), B
lymphocytes (CD19), or on the total CD4 (CD4CD3) and
CD8 (CD8CD3) T lymphocytes (data not shown). In contrast,
BALB/c splenocytes from noninfected mice presented a higher
percentage of CD4CD25 lymphocytes producing IL-10 when
compared with C57BL/6 (Fig. 5). However, this difference disap-
peared as early as 2 wk postinfection (Fig. 5).
Macrophages from BALB/c mice produce more IL-10 than those
from C57BL/6 mice upon in vitro infection with M. avium
Given that following infection, BALB/c mice accumulate more
macrophages in the spleen than C57BL/6, and that we were
FIGURE 5. BALB/c mice have more CD4CD25 T cells prone to produce IL-10 than C57BL/6. For IL-10 intracellular staining, splenocytes from
BALB/c and C57BL/6 mice noninfected and infected with 106 CFU of M. avium, were placed into culture with PMA and ionomycin in the presence of
brefeldin A for 4 h. A, Representative dot plot showing CD4 and CD25 expression on stimulated splenocytes from noninfected mice and the histograms
showing IL-10 production on CD4CD25 gated cells. B, Data are represented as the mean  SD of the percentage of IL-10-producing cells among the
CD4CD25 T lymphocyte from five mice per group from one of two independent experiments.
FIGURE 6. BMDM from BALB/c mice produce more IL-10 than those
from C57BL/6. BMDM from BALB/c and C57BL/6 mice were infected
with M. avium (0.5 106 cells with 106 M. avium CFU). At each day upon
infection, IL-10 production was measured in the culture supernatants by
ELISA. Data are represented as the mean SD from three culture wells for
each specific condition from one of four independent experiments.
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unable to clearly assess IL-10 production by CD11b cells us-
ing flow cytometry upon in vitro splenocyte stimulation, we
next studied the production of IL-10 by BMDM. Increased
amounts of IL-10 were produced by BALB/c BMDM upon M.
avium infection when compared with C57BL/6 (Fig. 6). More-
over, IL-10 became detectable by ELISA as early as 1 day
FIGURE 7. IL-10 activity contributes to the distinct susceptibility of BALB/c and C57BL/6 mice to M. avium infection. BALB/c and C57BL/6 mice
were infected i.v. with 106 CFU of M. avium. To abrogate IL-10 activity, mice were injected i.p. with 0.5 mg of anti-IL-10R mAb 1 day before infection,
followed by injections with 0.2 mg of anti-IL-10R mAb every other day until the end of the experiment. Control mice were submitted to the same protocol
of administration, being injected with nonimmune rat IgG. Bacterial load was determined, in spleen and liver, at different time points upon infection. Each
bar represents the mean  SD of the CFU from six mice per group from one of two independent experiments.
FIGURE 8. Complete absence of IL-10 improves resistance to M. avium infection in BALB/c but not in C57BL/6 mice. A, IL-10 KO and wild-type mice on the
BALB/c background (left panel) and on the C57BL/6 background (right panel) were infected with M. avium i.v. At different time points, the bacterial load was determined
in spleen and liver. Each point represents the meanSD of the CFU from six mice per group from one of two independent experiments for the BALB/c and four for the
C57BL/6 background. B, IFN- concentration was determined in the serum by ELISA before and 4 wk after M. avium infection of BALB/c wild-type and IL-10 KO. Data
are represented as the mean SD of IFN- concentration from five mice per group. BDL, Below detection level. C, BMDM from wild-type and IL-10 KO BALB/c mice
were infected with M. avium (0.5  106 cells with 106 M. avium CFU). Different doses of IFN- (1, 10, or 100 U) were given daily. The bacterial load was measured
4 h and 7 days upon infection. Data are represented as the mean  SD from three culture wells per specific condition from one of four independent experiments.
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postinfection in BALB/c BMDM and only 2 days later in
C57BL/6 (Fig. 6).
Blocking IL-10 activity attenuates differences in susceptibility to
M. avium between BALB/c and C57BL/6 mice
We next assessed whether IL-10 activity in vivo underlies the dif-
ferent susceptibility to infection by M. avium. We thus used an
anti-IL-10R mAb injected during the course of the infection by M.
avium in both mouse strains. Blocking the activity of IL-10 led to
a reduction in the bacterial load in the spleen and liver from both
strains (Fig. 7). However, this effect was clearly more pronounced
in BALB/c than in C57BL/6 mice (Fig. 7).
To further investigate whether the difference in susceptibility
to infection of these two mouse strains depends on IL-10 ac-
tivity, we next studied the course of M. avium infection using
IL-10 KO mice in the two genetic backgrounds. As shown in
Fig. 8A, the complete absence of IL-10 rendered BALB/c mice
more resistant to infection (decreased bacterial load in the
spleen from 4 wk postinfection onward in two independent ex-
periments), but the same was not observed for C57BL/6 mice.
In accordance, 4 wk postinfection serum levels of IFN- were
higher in the IL-10 KO animals when compared with the
BALB/c control mice (Fig. 8B). Using cultured BMDM from
BALB/c and IL-10 KO mice on a BALB/c background, we
found that the growth of M. avium inside macrophages was
reduced in cells from the latter strain. Administration of IFN-
to the cells strengthened the difference on the bacterial load
between wild-type and IL-10 KO (Fig. 8C).
Blocking IL-10 activity improves the efficacy of
antimycobacterial therapy in BALB/c but not in C57BL/6 mice
Previous results have shown that blocking IL-10 activity improved
the efficacy of antimycobacterial drugs in BALB/c mice during the
first 4 wk of treatment (19). Knowing that the different suscepti-
bility of BALB/c and C57BL/6 mice to M. avium infection de-
pends, at least partially, on distinct IL-10 activity, we next asked
whether the effect of IL-10 activity on the efficacy of the antimy-
cobacterial treatment also varied with the strains of mice. BALB/c
and C57BL/6 mice infected with M. avium were treated with an-
tibiotics alone or antibiotics plus anti-IL-10R mAb. Fig. 9A shows
that C57BL/6 mice were less susceptible to infection and that the
antimycobacterial drugs were more efficient in mice from this
strain. In addition, blocking IL-10 activity improved the efficacy of
antimycobacterial drugs in BALB/c mice but had no effect on
C57BL/6 mice. Of notice, while this effect was clearly observed in
the spleen and liver, it did not influence treatment efficacy in the
lung (data not shown).
Finally, we confirmed the relationship between the response
to antimycobacterial treatment and IL-10 in BALB/c mice by
studying the efficacy of antimycobacterial drugs in IL-10 KO
mice. In accordance with a negative relationship between IL-10
levels and treatment outcome, antibiotics were more effective in
FIGURE 9. Blocking IL-10 activity improves antimycobacterial therapy in BALB/c mice but not in C57BL/6. A, To abrogate IL-10 activity in M.
avium-infected animals, BALB/c and C57BL/6 mice were injected i.p. with 1 mg of anti-IL-10R mAb 4 wk after M. avium infection, followed by i.p.
injections with 0.2 mg of anti-IL-10R mAb every other day during 4 wk. Control mice were submitted to the same protocol of administration, being injected
with nonimmune rat IgG. Antibiotic therapy (Antib) was initiated 4 wk after infection until the end of the experimental period. Control mice were given
nonsupplemented water. B, IL-10 KO and wild-type mice on the BALB/c background infected with M. avium started antibiotic therapy 4 wk after infection.
At different time points, bacterial load was determined in spleen and liver. Each point represents the mean  SD CFU from five to six mice per group from
one of two independent experiments.
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BALB/c IL-10 KO mice than in the corresponding wild-type
animals (Fig. 9B).
Discussion
BALB/c mice have been shown to present increased susceptibility
to several intracellular pathogens when compared with other
strains such as C57BL/6 mice (2, 3, 35). In this study, we extend
these observations to infection by M. avium and suggest the basis
for such differences. Using BALB/c and C57BL/6 mice, the
present work shows that distinct activity of the anti-inflammatory
cytokine IL-10 impacts on the course of infection, conditioning not
only the susceptibility to mycobacteria but also the success of an-
timycobacterial therapy. In addition, our data help to clarify the
discordant results in the literature on the precise role of IL-10
during the immune response to mycobacterial infections.
Increased production of IL-10 has been clearly associated, in the
literature, with decreased resistance to infection with a diverse set
of intracellular pathogens (9) but this correlation is less clear in the
case of mycobacterial infections in mice. Thus, although blocking
studies have shown that endogenously produced IL-10 may exac-
erbate the infection, many reports where IL-10 KO mice were used
failed to substantiate the former observations. However, the latter
studies were performed using mutant mice on a pure C57BL/6 or
on a mixed C57BL/6.129 background (20–24). We now show that
upon M. avium infection splenocytes and macrophages from
C57BL/6 mice produce less IL-10 than the same cells from
BALB/c mice making the former strains less useful in identifying
a role for IL-10 than the latter. We believe that the use of different
mouse strains in previous studies may underlie the variability of
the data generated by different authors. Although in in vitro sys-
tems, we clearly showed an increased production of IL-10 by total
splenocytes and BMDM from BALB/c when compared with
C57BL/6 mice, we were unable to demonstrate distinct levels of
IL-10 in the serum of the two mouse strains. Therefore, although
our results with in vivo systems clearly showed that IL-10 activity
is associated with distinct susceptibility of mice to M. avium, we
should next investigate the mechanisms underlying such differ-
ences. This will help us elucidate the precise involvement of
IL-10 in the increased susceptibility of BALB/c mice to infec-
tion by M. avium.
Also of relevance is the observation that the effect of IL-10
activity abrogation on mycobacterial growth was not exactly the
same in the two in vivo models studied: administration of anti-IL-
10R Abs in wild-type mice or the use of IL-10 KO mouse strains.
Neutralization of IL-10 activity using specific Abs was more ef-
ficient in improving resistance to infection in wild-type mice than
that observed with IL-10 KO animals. This may be related to com-
pensatory mechanisms developed when a particular immunoregu-
latory cytokine is congenitally absent, as is the case when IL-10
KO animals are studied. In the context of immune response to
infection, we believe the model in which IL-10 activity is blocked
in a wild-type background during the course of infection is more
informative.
The production of IL-10 upon infection with mycobacteria cer-
tainly also depends on factors other than the genetic background.
The virulence of the mycobacterial strain used, the infection route,
and the infectious dose are also expected to influence the immune
response to infection. For example, Wakeham et al. (36) showed
that C57BL/6 mice were less susceptible to i.v. infection with ba-
cillus Calmette-Gue´rin than BALB/c mice, whereas such a differ-
ence was not found upon infection with an 8-fold smaller intra-
tracheal inoculum (37). IL-10 seems also to differentially influence
the different organs studied within each mouse strain. As we show
here in a model of infection by M. avium, the spleen is more
susceptible to the action of IL-10 than the liver, while the lung
seems refractory. This may be related to the nature of the phago-
cytosing macrophage, i.e., alveolar macrophages, Kupffer cells, or
splenic macrophages may respond differently upon mycobacterial
infections.
IL-10 is produced by several types of cells of the immune sys-
tem including the most relevant cells that fight mycobacterial in-
fections: CD4 T cells and macrophages. Although IL-10 pro-
duced by T cells has been initially associated with Th2-type CD4
T cells, it is now clear that regulatory T cells can also produce
great amounts of IL-10 (38) and that even Th1 cells produce this
cytokine albeit in minute amounts (39). We found that normal
BALB/c have more CD4CD25 T cells than C57BL/6 mice,
confirming previous data from another laboratory (40). In ad-
dition, BALB/c mice have more CD4CD25 as well as CD4
CD25Foxp3 or IL-10-secreting CD4CD25 T cells at the mo-
ment of infection, suggesting that these cells could be the source of
the different amounts of IL-10 produced by splenocytes from in-
fected mice in the two mouse strains. Moreover, the number of
macrophages in the spleen at 2 wk postinfection was higher in
BALB/c than in C57BL/6 mice and the BALB/c mice BMDM
produced more IL-10 upon M. avium infection than the ones from
C57BL/6 mice. Although these differences disappear as the infec-
tion progresses, we propose that they determine the course of the
infection at its early onset as it has been shown that the initial
response to the pathogen can determine the overall course of the
infection (41, 42).
The initial difference on IL-10 production seems to condition
not only the host’s ability to fight the mycobacterial infection but
also the response to antimycobacterial therapy. After 4 wk, al-
though higher in BALB/mice, the bacterial load showed a clear
tendency to stabilize in the spleen and liver of both mouse strains.
It was at this stage that treatment to block IL-10 activity started.
Remarkably, the administration of anti-IL-10R mAb improved an-
timycobacterial therapy efficacy in BALB/c but not in C57BL/6
mice. Moreover, although the anti-IL-10R mAb was administered
exclusively during the first 4 wk of antimycobacterial treatment
(from the fourth to the eighth week postinfection), the effect on the
efficacy of the chemotherapy was not just observed during this
period but was evident for at least another 4 wk after the anti-IL-
10R mAb administration was stopped. These observations strongly
suggest that reducing IL-10 activity can improve the efficacy of
antibiotic therapy in infections by M. avium.
The present data may have important implications for research
involving mycobacterial infection in humans. A set of reports in
the literature associate the increased production of IL-10 with in-
creased susceptibility to tuberculosis (27–30) and to M. avium
(26). Moreover, distinct IL-10 production has also been associated
with different forms of mycobacterial infections. In Buruli ulcer,
cells from ulcerative lesions have been shown to express more
IL-10 mRNA than the early nodular lesions (32); higher produc-
tion of IL-10 by blood cells occurs in patients with the most ad-
vanced form of the disease (established ulcers) than in patients
exclusively with early nodular lesions (31). In addition, IL-10 gene
polymorphisms were associated with distinct susceptibility to in-
fection with Mycobacterium leprae (43) and with different forms
of tuberculosis (44). In accordance, two recent reports showed that
patients with tuberculosis present an increased percentage of reg-
ulatory T cells in the blood (45, 46). In light of these recent find-
ings and of our results, it seems clear that the host’s IL-10 activity
during mycobacterial infections relates to susceptibility/resistance
to infection. The evidence that reducing or blocking IL-10 activity
8034 IL-10 ACTIVITY UNDERLIES MICE SUSCEPTIBILITY TO M. avium
improves antimycobacterial therapy should be considered as a rea-
sonable strategy to increase the efficacy of treatment in a particular
group of patients.
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